Novocure (NVCR) Misses Q4 EPS by 1c

Novocure (NASDAQ: NVCR) reported Q4 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $53.7 million versus the consensus estimate of $53.52 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance
• Vera Bradley (VRA) Misses Q1 EPS by 26c ; Offers Guidance